White Atractylodes for Health & Longevity

Created on 11/13/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Unknown – Audit

White Atractylodes is a dried East Asian herbal stem used for digestion and vitality. Human evidence remains rated Low at best and indirect: multi-herb formulas show bowel, blood sugar, and blood pressure signals, with aging effects confined to rodent and cell studies. Short-term oral use appears generally well tolerated, but long-term safety data are absent and laboratory studies flag theoretical bleeding, birth-defect, and drug-interaction risks. (Full Review)

Protocol

Standard decoction and granule regimens
15–30 g/day dried rhizome
Typically honey-bran-fried decoction for digestive weakness; Shenling Baizhu granules 6 g thrice daily
Best time of day
30 minutes after morning and evening meals
Administered warm after food rather than cold on an empty stomach
Expected half-life and split dosing
Twice-daily or thrice-daily dosing
Human half-life is unmeasured; rat atractylenolide III half-life 0.85 hours, 12-hour lactone detection
Time to effect
Chronic diarrhea
10 days to 24 weeks
Multi-herb Shenling Baizhu San trial span; indirect standalone evidence
Glycemic control in type 2 diabetes
10 days to 3 months
Multi-herb Qiwei Baizhu San trial span; HbA1c rechecked at 12 weeks
Appetite and functional scores
3–7 weeks
Purified atractylenolide I pilot in gastric cancer wasting, not longevity

Benefits

Contraindications
  • Pregnant or lactating women
  • Individuals with Asteraceae (ragweed, chrysanthemum) hypersensitivity
  • Active bleeding, thrombocytopenia (<100,000/µL), or surgery within 14 days
  • Acute hepatitis, ALT/AST >5× ULN, or decompensated cirrhosis (Child-Pugh Class B/C)
Key Interactions
Theoretical (inferred from mechanism)
  • Prescription anticoagulants and antiplatelets (warfarin, clopidogrel)
  • Over-the-counter antiplatelet and pain medications (aspirin, ibuprofen)
  • CYP3A4-metabolized and P-gp-transported drugs (cyclosporine, atorvastatin, digoxin)
  • Antidiabetic and aldosterone-blocking medications (insulin, metformin, spironolactone)
  • Supplements with antiplatelet, glucose-lowering, or coumarin activity (omega-3 fish oil, berberine, cassia cinnamon)
  • Elective surgery and prolonged fasting regimens

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild gastrointestinal upset and dry mouth
  • Speculative: Embryotoxicity and congenital limb malformations; platelet inhibition and prolonged bleeding; coumarin-potentiated hepatocyte toxicity; hypoglycemia or aldosterone-mediated electrolyte shifts

Monitoring

Marker Target Why
Serum ALT and AST ALT: 19–25 IU/L in females, 29–33 IU/L in males; AST: 10–40 IU/L Detects herb- or interaction-related liver injury
Fasting plasma glucose 70–99 mg/dL Tracks glucose lowering and screens for hypoglycemia
HbA1c 4.0–5.6% Evaluates three-month glycemic response
Serum potassium 3.5–5.0 mmol/L Monitors electrolytes given diuretic actions and preclinical aldosterone inhibition
Bilirubin Not specified in the ER Paired with ALT and AST for liver-injury stopping thresholds
Seated blood pressure Not specified in the ER Safety check commonly paired with morning serum potassium draw

Cadence: At baseline, then ALT, AST, fasting plasma glucose, and serum potassium at 4–8 weeks after initiation or dose escalation, HbA1c at 12 weeks, and the complete panel every 6 months during extended cyclical use, with prompt unscheduled testing for persistent nausea, dark urine, dizziness, or unusual bruising.

Qualitative Assessment

  • Stool form (Bristol Stool Form Scale) and bowel frequency
  • Post-meal comfort, appetite, and absence of nausea or dry mouth
  • Daytime energy and absence of easy bruising